INSM - インスメッド (Insmed Inc.) インスメッド

 INSMのチャート


 INSMの企業情報

symbol INSM
会社名 Insmed Inc (インスメッド)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 インスメッド(Insmed Incorporated)は希少疾患セグメント患者の治療法の開発・商品化を通じて運営するバイオ医薬品会社である。リード製品候補は、マイコバクテリウム・アビウム複合体(MAC)によって引き起こされる治療不応性非結核性マイコバクテリア(NTM)肺疾患の成人患者のための後期段階にある吸入用LAI(ARIKAYCE)、または吸入用リポソームアミカシンである。その初期段階のパイプラインには、メチシリン耐性黄色ブドウ球菌およびNTMを含む、満たされていない医療ニーズの複数のまれな疾患で同社が評価している前臨床化合物が含まれる。初期の臨床段階のパイプラインにはINS1007とINS1009が含まれる。INS1007は、ジペプチジルペプチダーゼ1の経口可逆阻害剤である。INS1009は、肺動脈性高血圧症を含む稀な肺疾患のための差別化された製品プロファイルを提供し得るトレプロスチニルプロドラッグの吸入ナノ粒子製剤である。同社はINS1009の第I相試験を完了した。   インスメッドは、米国のバイオ医薬品メ―カ―。肺疾患の患者向けの吸入治療法を開発し、商品化する。主力製品候補は、肺感染症の吸入抗生物質治療薬「ARIKAYCE(吸入用のリポソ―ム性アミカシン)」である。非結核性抗酸菌症(NTM)による肺感染患者による第2相試験と、緑膿菌の肺感染を伴う嚢胞性線維症(CF)患者による第3相臨床試験を完了した。   Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United Statesand the European Union to treat a chronic, debilitating lung disease. The Company is also progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is headquartered in Bridgewater, New Jersey, with a growing footprint across Europeand in Japan. .
本社所在地 10 Finderne Avenue Building 10 Bridgewater NJ 08807 USA
代表者氏名 William H. Lewis ウィリアムH.ルイス
代表者役職名 President Chief Executive Officer Director 社長兼最高経営責任者(CEO)
電話番号 +1 908-977-9900
設立年月日 36465
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 214人
url www.insmed.com
nasdaq_url https://www.nasdaq.com/symbol/insm
adr_tso
EBITDA EBITDA(百万ドル) -241.92400
終値(lastsale) 16.93
時価総額(marketcap) 1304301725.94
時価総額 時価総額(百万ドル) 1264.24
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 937.06700
当期純利益 当期純利益(百万ドル) -255.52400
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Insmed Incorporated revenues was not reported. Net loss increased 77% to $145M. Higher net loss reflects General and Administrative - other increase from $59K to $62.1M (expense) Research and development -other increase of 83% to $61.2M (expense) Interest expense increase from $3M to $12.1M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$1.32 to -$1.89.

 INSMのテクニカル分析


 INSMのニュース

   Brokerages Expect Insmed Incorporated (NASDAQ:INSM) to Post -$0.84 EPS  2021/10/30 18:20:46 Transcript Daily
Wall Street brokerages predict that Insmed Incorporated (NASDAQ:INSM) will post earnings per share of ($0.84) for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Insmeds earnings. The highest EPS estimate is ($0.76) and the lowest is ($0.98). Insmed reported earnings of ($1.00) per share in the same quarter []
   $54.63 Million in Sales Expected for Insmed Incorporated (NASDAQ:INSM) This Quarter  2021/10/30 18:20:42 Dakota Financial News
Equities research analysts expect Insmed Incorporated (NASDAQ:INSM) to announce sales of $54.63 million for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for Insmeds earnings, with estimates ranging from $51.60 million to $58.63 million. Insmed reported sales of $41.42 million during the same quarter last year, which indicates a positive year over []
   Insmed (NASDAQ:INSM) Posts Quarterly Earnings Results, Misses Estimates By $0.13 EPS  2021/10/29 03:24:41 Dakota Financial News
Insmed (NASDAQ:INSM) released its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.83) by ($0.13), MarketWatch Earnings reports. Insmed had a negative net margin of 219.67% and a negative return on equity of 105.70%. The firm had revenue of […]
   Insmed Incorporated''s (INSM) CEO Will Lewis on Q3 2021 Results - Earnings Call Transcript  2021/10/28 18:53:11 Seeking Alpha
   Brokerages Anticipate Insmed Incorporated (NASDAQ:INSM) Will Announce Earnings of -$0.83 Per Share  2021/10/28 16:03:05 Dakota Financial News
Analysts predict that Insmed Incorporated (NASDAQ:INSM) will announce earnings per share (EPS) of ($0.83) for the current quarter, Zacks reports. Four analysts have made estimates for Insmeds earnings. The lowest EPS estimate is ($0.93) and the highest is ($0.74). Insmed reported earnings of ($0.63) per share in the same quarter last year, which would indicate []
   Insmed Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update  2021/02/25 12:30:00 PR Newswire
BRIDGEWATER, N.J., Feb. 25, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the fourth quarter and full year ended December 31,…
   Insmed Does Earnings Surprise History Hold Any Clue for Stock market Insights & financial analysis  2021/02/24 14:08:00 Stock Market Daily
Insmed announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Insmed to Present at Two March Conferences  2021/02/24 13:00:00 PR Newswire
BRIDGEWATER, N.J., Feb. 24, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will participate in the following virtual investor…
   Insmed Announces Topline Results from Phase 1 Study of Treprostinil Palmitil Inhalation Powder (TPIP)  2021/02/19 12:30:00 PR Newswire
BRIDGEWATER, N.J., Feb. 19, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced topline results from the Phase 1 study of treprostinil palmitil inhalation…
   Insmed to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call on Thursday, February 25, 2021  2021/02/12 13:00:00 PR Newswire
BRIDGEWATER, N.J., Feb. 12, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its fourth quarter and full year 2020 financial…
   Insmed Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update  2021/02/25 12:30:00 PR Newswire
BRIDGEWATER, N.J., Feb. 25, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the fourth quarter and full year ended December 31,…
   Insmed Does Earnings Surprise History Hold Any Clue for Stock market Insights & financial analysis  2021/02/24 14:08:00 Stock Market Daily
Insmed announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Insmed to Present at Two March Conferences  2021/02/24 13:00:00 PR Newswire
BRIDGEWATER, N.J., Feb. 24, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will participate in the following virtual investor…
   Insmed Announces Topline Results from Phase 1 Study of Treprostinil Palmitil Inhalation Powder (TPIP)  2021/02/19 12:30:00 PR Newswire
BRIDGEWATER, N.J., Feb. 19, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced topline results from the Phase 1 study of treprostinil palmitil inhalation…
   Insmed to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call on Thursday, February 25, 2021  2021/02/12 13:00:00 PR Newswire
BRIDGEWATER, N.J., Feb. 12, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its fourth quarter and full year 2020 financial…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 インスメッド INSM Insmed Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)